In recent years, clinical research has placed growing emphasis on health conditions uniquely affecting men, addressing long-overlooked issues such as testosterone deficiency, erectile dysfunction, and prostate diseases. Among these, Chronic Bacterial Prostatitis (CBP) is emerging as a condition of high interest due to its prevalence, recurrence, and negative impact on quality of life.
Understanding Chronic Bacterial Prostatitis (CBP)
CBP is a recurrent, painful urological condition that primarily affects men, often characterized by urinary tract infections and persistent prostate inflammation. It is one of the most common urological diagnoses in men under 50. While long-term antibiotic therapy remains the standard treatment, many patients continue to experience symptom relapse — highlighting the urgent need for more holistic and effective treatment strategies.
Innovative Clinical Trial: Antibiotics and Nutraceutical Integration
To address this gap, 1MED supported the management of a recent randomized, placebo-controlled clinical trial aimed at evaluating a nutraceutical supplement as an adjunct to antibiotic therapy in patients with CBP. This innovative study design explored the potential of probiotic supplementation to reduce symptom recurrence, improve quality of life, and enhance treatment satisfaction.
Study Design Highlights:
-
72 male patients under standard antibiotic treatment for CBP were enrolled at a specialized urologic center.
-
Patients were randomized (1:1) to receive either the investigational probiotic supplement or placebo, alongside their antibiotic regimen.
-
A total of 7 patient visits were scheduled over 24 weeks, with assessments including clinical exams, lab tests, questionnaires, and gut microbiota analysis.
-
Standardized tools like the NIH-CPSI and SF-12 questionnaires were used to evaluate symptom severity, quality of life, and patient satisfaction.
Key Objectives and Endpoints
Primary Objective:
-
Evaluate the probiotic’s impact on reducing the number of symptomatic recurrences in CBP patients.
Secondary Objectives:
-
Reduce risk of CBP recurrence
-
Assess impact on quality of life
-
Measure symptom relief
-
Track bowel habits and gut health
-
Monitor use of rescue medications
-
Determine overall treatment satisfaction
-
Record adverse events
Exploratory endpoints included analysis of gut microbiota, SCFAs, amino acid derivatives, and strain recovery from stool samples.
1MED’s Full-Service Role in the Trial
1MED played a pivotal role in the planning, execution, and management of this clinical study, providing:
-
Protocol development and preparation of study tools
-
Site selection and feasibility
-
Regulatory submissions and ethics committee liaison
-
Study start-up and ongoing monitoring
-
Data management and biostatistics
-
Study close-out and reporting
1MED also ensured strict compliance with GCP guidelines, maintaining high standards for quality assurance, participant safety, and regulatory alignment.
Promising Outcomes: A New Path for CBP Treatment
Although final results are pending publication, preliminary data suggest:
-
A significant reduction in recurrence rates
-
Improved NIH-CPSI and SF-12 scores
-
Enhanced patient-reported satisfaction
-
Potential link between gut microbiota modulation and symptom control
These results point toward a new, patient-centered approach to CBP treatment: combining standard antibiotic therapy with nutraceutical supplementation to not only treat the infection but also strengthen the underlying microbial and immune environment.
The Future of Men’s Health Research
This trial exemplifies how well-designed clinical studies can deliver breakthroughs in men’s health, a field that has historically been underrepresented. Increasing male participation in clinical trials is vital for driving evidence-based, gender-specific treatments.
1MED remains committed to advancing research in urology and men’s health by supporting innovative, high-quality clinical development programs from preclinical through regulatory approval and post-market phases.